BioSpace News Archive

Lucence, will present promising new data on the extension of its amplicon-based next generation sequencing (NGS) assays to new applications at the 58th Annual Meeting of the American Society of Clinical Oncology in-person in Chicago, from June 3rd to June 7th, 2022.

Stryker (NYSE:SYK) today announced that its Q Guidance System received 510(k) clearance from the U.S. Food and Drug Administration.

Paxman will be thanking partners from across the Oncology speciality for their overwhelming support in implementation of their pioneering scalp cooling system throughout the US and the world as they participate at this year’s ASCO Annual Meeting.

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) today announces its financial results for the first quarter.

FibroBiologics, will present preclinical and safety-centered limited clinical trial data for the single-dose infusion of tolerogenic human dermal fibroblasts (HDFs) data at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting being held in person from June 1 – 4, at the Gaylord National Resort and Convention Center in National Harbor, Maryland.

After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment.

GRAIL, LLC, announced today a collaboration with the U.S. Department of Veterans Affairs (VA) Veterans Health Administration, America’s largest integrated health care system, and the Veterans Health Foundation to provide Galleri®, GRAIL’s groundbreaking multi-cancer early detection (MCED) blood test, to 10,000 veterans across approximately 10 participating VA sites over the next three years.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutic drugs that change the way degenerative muscle diseases are treated, today announced its unaudited financial results and operational highlights for the quarter ended March 31, 2022 (“Q1 2022").

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has hired Dr. Brian S. Cornblatt as its Chief Medical Officer, marking a significant milestone in the Company’s route for the development of next generation therapeutic solutions including botanical drugs.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) announces that it has completed the validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow.